SUMMARY OF INDIRECT COMPARISON TO EVALUATE EFFICACY OF BARICITINIB WITH TARGETED SYNTHETIC AND BIOLOGIC DISEASE ANTI-RHEUMATIC DRUGS IN PATIENTS WITH RHEUMATOID ARTHRITIS

被引：0
|
作者：
Emery, Paul [1 ]
Dudler, Jean [2 ]
Smolen, Josef [3 ]
Zerbini, Cristiano [4 ]
Burmester, Gerd [5 ]
Fautrel, Bruno [6 ]
van der Laar, Mart [7 ]
Fleischmann, Roy [8 ]
Fakhouri, Walid [9 ]
De Leonardis, Francesco [10 ]
Zhu, Baojin [11 ]
Kadziola, Zbigniew [12 ]
De La Torre, Inmaculada [13 ]
Perrier, Clementine [14 ]
Taylor, Peter C. [15 ]
机构：
[1] Leeds MSK Biomed Chapel Allerton Hosp, Fac Med & Hlth, Leeds, W Yorkshire, England
[2] HFR Fribourg Hop Cantonal, Dept Rheumatol, Fribourg, Switzerland
[3] Med Univ Vienna, Dept Rheumatol, Vienna, Austria
[4] Ctr Invest Clin, Dept Rheumatol, Sao Paulo, Brazil
[5] Charite Univ Med Berlin, Dept Rheumatol & Clin Immunol, Berlin, Germany
[6] Pierre & Marie Curie Univ, Dept Rheumatol, Paris, France
[7] Arthrit Ctr Twente, Dept Rheumatol, Enschede, Netherlands
[8] Univ Texas Southwestern Med Ctr Dallas, Dept Internal Med, Dallas, TX 75390 USA
[9] Eli Lilly & Co, Global Hlth Outcomes, Indianapolis, IN 46285 USA
[10] Eli Lilly & Co, Dept Rheumatol, Indianapolis, IN 46285 USA
[11] Eli Lilly & Co, Real World Analyt Immunol, Indianapolis, IN 46285 USA
[12] Eli Lilly & Co, Real World Analyt Capabil & Data Mart, Indianapolis, IN 46285 USA
[13] Eli Lilly & Co, Dept Med, Indianapolis, IN 46285 USA
[14] Eli Lilly & Co, Dept Med Autoimmune, Indianapolis, IN 46285 USA
[15] Univ Oxford, Botnar Res Ctr, NDORMS, Headington, England
来源：
RHEUMATOLOGY | 2019年 / 58卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
074
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Summary of indirect comparisons to evaluate efficacy of baricitinib with targeted synthetic and biologic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis
    Emery, P.
    Dudler , J.
    Smolen, J.
    Zerbini, C.
    Burmester, G.
    Fautrel, B.
    van de Laar, M.
    Fleischmann, R.
    Fakhouri, W.
    De Leonardis, F.
    Zhu, B.
    Kadziola, Z.
    De La Torre, I
    Perrier, C.
    Taylor, P.
    SWISS MEDICAL WEEKLY, 2019, : 7S - 8S
  • [2] USE OF BIOLOGIC OR TARGETED SYNTHETIC DISEASE MODIFYING ANTI-RHEUMATIC DRUGS AND THE RISK OF LYMPHOMA IN RHEUMATOID ARTHRITIS
    Singh, N.
    Peterson, A.
    Baraff, A.
    Bhatti, P.
    Gopal, A.
    Smith, N.
    Barton, J.
    Curtis, J.
    Li, C.
    Weiss, N.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 1060 - 1061
  • [3] Use of Biologic or Targeted Synthetic Disease Modifying Anti-rheumatic Drugs and the Risk of Lymphoma in Rheumatoid Arthritis
    Singh, Namrata
    Peterson, Alexander
    Baraff, Aaron
    Gopal, Ajay
    Smith, Nicholas
    Barton, Jennifer
    Curtis, Jeffrey
    Weiss, Noel
    ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 2381 - 2382
  • [4] Comparative Safety of Biologic and Targeted Synthetic Disease Modifying Anti-Rheumatic Drugs for Cancer in Rheumatoid Arthritis
    Sendaydiego, Xavier
    Gold, Laura
    Liew, Jean
    Wysham, K.
    Dubreuil, Maureen
    Andrews, James
    Reid, Pankti
    Liew, David
    Goulabchand, Radjiv
    Singh, Abha
    Hughes, Grant
    Pioro, Mathilde
    Sparks, Jeffrey
    Jarvik, Jeffrey
    Singh, Siddharth
    Singh, Namrata
    ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 3333 - 3336
  • [5] Effectiveness of sequential biologic and targeted disease modifying anti-rheumatic drugs for rheumatoid arthritis
    Zhao, Sizheng Steven
    Kearlsey-Fleet, Lianne
    Bosworth, Ailsa
    Watson, Kath
    Hyrich, Kimme L.
    RHEUMATOLOGY, 2022, 61 (12) : 4678 - 4686
  • [6] Comparative Safety of Biologic and Targeted Synthetic Disease Modifying Anti-Rheumatic Drugs for Cardiovascular Outcomes in Rheumatoid Arthritis
    Sendaydiego, Xavier
    Gold, Laura
    Wysham, K.
    Liew, Jean
    Dubreuil, Maureen
    Andrews, James
    Reid, Pankti
    Liew, David
    Goulabchand, Radjiv
    Singh, Abha
    Hughes, Grant
    Pioro, Mathilde
    Sparks, Jeffrey
    Jarvik, Jeffrey
    Singh, Siddharth
    Singh, Namrata
    ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 848 - 850
  • [7] Comparative safety of biologic and targeted synthetic disease-modifying anti-rheumatic drugs for cardiovascular outcomes in rheumatoid arthritis
    Sendaydiego, Xavier
    Gold, Laura S.
    Dubreuil, Maureen
    Andrews, James S.
    Reid, Pankti
    Liew, David F. L.
    Goulabchand, Radjiv
    Hughes, Grant C.
    Sparks, Jeffrey A.
    Jarvik, Jeffrey G.
    Singh, Siddharth
    Liew, Jean W.
    Singh, Namrata
    RHEUMATOLOGY, 2025,
  • [8] SARCOPENIA IN PATIENTS WITH RHEUMATOID ARTHRITIS ON THE TREATMENT WITH BIOLOGIC DISEASE MODIFYING ANTI-RHEUMATIC DRUGS
    Hasegawa, E.
    Ito, S.
    Kurosawa, Y.
    Taniguchi, S.
    Kobayashi, D.
    Abe, A.
    Otani, H.
    Nakazono, K.
    Murasawa, A.
    Narita, I.
    Ishikawa, H.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 985 - 985
  • [9] ADHERENCE TO BIOLOGIC AND CONVENTIONAL DISEASE MODIFYING ANTI-RHEUMATIC DRUGS IN PATIENTS WITH RHEUMATOID ARTHRITIS
    Mishra, P.
    VALUE IN HEALTH, 2018, 21 : S198 - S198
  • [10] Comparison of remission criteria in patients with rheumatoid arthritis treated with biologic or targeted synthetic disease- modifying anti-rheumatic drugs: results from a nationwide registry
    Koh, Jung Hee
    Lee, Yusun
    Kim, Hyoun-Ah
    Kim, Jinhyun
    Shin, Kichul
    THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE, 2022, 14
12345